ValuEngine upgraded shares of MYOS (NASDAQ:MYOS) from a hold rating to a buy rating in a research report sent to investors on Friday morning.
Shares of NASDAQ MYOS traded up $0.07 on Friday, reaching $1.22. 16,592 shares of the company’s stock traded hands, compared to its average volume of 128,726. MYOS has a 12 month low of $1.03 and a 12 month high of $2.50. The company has a market capitalization of $8.06 million, a price-to-earnings ratio of -1.77 and a beta of 1.42.
MYOS (NASDAQ:MYOS) last announced its earnings results on Wednesday, August 8th. The company reported ($0.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.06). MYOS had a negative net margin of 883.55% and a negative return on equity of 101.86%. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.20 million. As a group, research analysts forecast that MYOS will post -0.6 earnings per share for the current year.
MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Featured Story: Why do companies issue stock splits?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with MarketBeat.com's FREE daily email newsletter.